# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2021 Earnings Results

**Report date:** 2021-11-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2021

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.69%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $15.37 | N/A | +56.64% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the earnings per share results, highlighting the strength of their product pipeline. However, they did not provide specific future guidance.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on advancing our pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates robust profitability, but the stock's slight decline of 0.69% suggests that investors may have been expecting more comprehensive guidance or revenue details. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2021_